TRCT
ACRS icon

Tower Research Capital (TRC)’s Aclaris Therapeutics ACRS Stock Holding History

Tower Research Capital (TRC)’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.5K Buy
3,867
+117
+3% +$395 ﹤0.01% 3701
2025
Q4 		$11.3K Sell
3,750
-2,750
-42% -$6.95K ﹤0.01% 3619
2025
Q3 		$12.3K Buy
+6,500
New +$11.3K ﹤0.01% 3788
2025
Q2 		– Sell
-3,413
Closed -$5.15K – 5239
2025
Q1 		$5.15K Sell
3,413
-14,506
-81% -$30.9K ﹤0.01% 4154
2024
Q4 		$44.4K Sell
17,919
-3,990
-18% -$9.93K ﹤0.01% 2626
2024
Q3 		$25.2K Buy
21,909
+1,843
+9% +$2.26K ﹤0.01% 3103
2024
Q2 		$22.1K Buy
20,066
+14,799
+281% +$17.4K ﹤0.01% 3700
2024
Q1 		$6.53K Sell
5,267
-4,477
-46% -$5.34K ﹤0.01% 4353
2023
Q4 		$10.2K Buy
9,744
+5,480
+129% +$16.7K ﹤0.01% 4273
2023
Q3 		$29.2K Buy
4,264
+3,056
+253% +$26.1K ﹤0.01% 3046
2023
Q2 		$12.5K Sell
1,208
-870
-42% -$7.87K ﹤0.01% 3862
2023
Q1 		$17K Buy
2,078
+1,438
+225% +$18.3K ﹤0.01% 3607
2022
Q4 		$10K Sell
640
-7,291
-92% -$117K ﹤0.01% 3938
2022
Q3 		$125K Sell
7,931
-5,269
-40% -$83K ﹤0.01% 2366
2022
Q2 		$184K Buy
13,200
+11,900
+915% +$167K ﹤0.01% 1817
2022
Q1 		$22K Sell
1,300
-151
-10% -$2.06K ﹤0.01% 3421
2021
Q4 		$22K Sell
1,451
-5,219
-78% -$79.1K ﹤0.01% 3542
2021
Q3 		$120K Sell
6,670
-1,787
-21% -$28.6K ﹤0.01% 2232
2021
Q2 		$149K Buy
8,457
+7,766
+1,124% +$176K ﹤0.01% 2132
2021
Q1 		$17K Buy
691
+418
+153% +$8.17K ﹤0.01% 3989
2020
Q4 		$2K Buy
+273
New +$1.15K ﹤0.01% 4864
2020
Q1 		– Sell
-218
Closed – – 2960
2019
Q4 		$0 Sell
218
-5,556
-96% -$9.21K ﹤0.01% 3444
2019
Q3 		$7K Buy
+5,774
New +$8.19K ﹤0.01% 3119
2019
Q2 		– Sell
-946
Closed -$6K – 3592
2019
Q1 		$6K Buy
+946
New +$6.27K ﹤0.01% 2923
2018
Q4 		– Sell
-464
Closed -$7K – 3774
2018
Q3 		$7K Buy
+464
New +$7.95K ﹤0.01% 2939
2018
Q1 		– Sell
-47
Closed -$1K – 3184
2017
Q4 		$1K Buy
47
+20
+74% +$487 ﹤0.01% 3314
2017
Q3 		$1K Buy
+27
New +$724 ﹤0.01% 3636
2017
Q2 		– Sell
-87
Closed -$3K – 2625
2017
Q1 		$3K Buy
+87
New +$2.51K ﹤0.01% 2429
2016
Q3 		– Sell
-100
Closed -$2K – 3549
2016
Q2 		$2K Sell
100
-86
-46% -$1.7K ﹤0.01% 3850
2016
Q1 		$4K Sell
186
-626
-77% -$12K ﹤0.01% 2841
2015
Q4 		$22K Buy
+812
New +$15.8K ﹤0.01% 1188

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Tower Research Capital (TRC)'s ACRS Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Aclaris Therapeutics (ACRS) stake by 3.1% in Q1 2026, buying an estimated $395 and bringing the position to 3,867 shares worth $14.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3701.

Tower Research Capital (TRC) first reported a position in ACRS in Q4 2015 and has held it in 31 quarters since. The position peaked at $184K in Q2 2022. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Tower Research Capital (TRC) held 3,867 shares of Aclaris Therapeutics worth $14.5K as of Q1 2026.
  • Tower Research Capital (TRC) bought 117 Aclaris Therapeutics shares in Q1 2026, an estimated $395.
  • Aclaris Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3701 holding.
  • Tower Research Capital (TRC) first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 31 quarters since.
  • Tower Research Capital (TRC)'s Aclaris Therapeutics position peaked at $184K in Q2 2022.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.